Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
DGLA–ACSL4 Ferroptosis in AML Cells
2026-10-06
Jiang and colleagues identify dihomo-γ-linolenic acid (DGLA) as a lipid-metabolic trigger of ferroptosis in acute myeloid leukemia cells and connect this effect to ACSL4-dependent remodeling of polyunsaturated fatty acid metabolism. The study combines targeted metabolomics, genetic perturbation, cell-based evidence, and an in vivo dietary model, while also highlighting the limits of translating ferroptosis findings from experimental AML systems to clinical treatment.
Sucrose in Human Microglia Research: Evidence and Limits
2026-10-06
Sucrose can influence how biological samples are stabilized and interpreted, but it should not be mistaken for a demonstrated driver of microglial biology. This article places sucrose in the context of the human microglia transplantation model reported by Serneels et al., separating established findings from plausible methodological considerations.
EDC.HCl Product Overview and Evidence Limits
2026-10-05
EDC.HCl is a water-soluble carbodiimide reagent listed by APExBIO for conceptual use in amide-bond-forming chemistry, peptide synthesis, and bioconjugation. No matched paper evidence is available for this product overview.
Saracatinib: Interpreting Src Signaling Across Models
2026-10-05
Saracatinib (AZD0530) is examined here as a mechanistic perturbation tool for cancer biology and synaptic signaling research. This article connects Src-family kinase biology with the Reelin–Apoer2–SFK findings reported in PNAS while emphasizing evidence boundaries, model differences, and interpretation.
How Imidazoline Antagonists Raise Insulin Release
2026-10-04
The 1992 study by Jonas, Plant, and Henquin showed that several imidazoline α2-adrenoceptor antagonists increase insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than only by blocking adrenergic receptors. By combining insulin secretion measurements with 86Rb efflux and patch-clamp analyses, the paper linked pharmacological effects to β-cell ion-channel activity while also defining important limits of that interpretation.
EZ Cap™ Human PTEN mRNA: Evidence Context
2026-10-03
This overview places EZ Cap™ Human PTEN mRNA within current cancer research on tumor suppressor gene mRNA and nanoparticle delivery. It distinguishes supplier-described molecular features from published preclinical evidence, emphasizing that nitric-oxide-mediated vascular barrier modulation has not yet been shown to deliver PTEN mRNA or restore PTEN signaling in humans.
HNRNPU K181 Lactylation Rewires Cervical Cancer
2026-10-02
This Advanced Science study identifies HNRNPU lysine 181 lactylation as a non-histone regulatory event that links lactate accumulation to PHGDH expression, serine biosynthesis, and cervical cancer growth. Its combination of proteomic discovery, RNA-centered mechanistic analysis, and in vitro and in vivo validation provides a framework for studying how metabolic signals reshape post-transcriptional gene regulation.
Exendin-4: From GLP-1 Mechanism to Access
2026-10-01
Exendin-4, also known as Exenatide in therapeutic contexts, is more than a GLP-1 receptor agonist: it is a mechanistic probe for cAMP signaling, beta cell performance, metabolic disease, and emerging access models. This thought-leadership article connects assay design with yeast-based production research while separating demonstrated evidence from translational opportunity.
Phillygenin and Signaling in Diabetic Nephropathy
2026-10-01
The reference study shows that phillygenin protects against diabetic nephropathy by coordinating suppression of TLR4/MyD88/NF-κB-associated inflammation with restoration of PI3K/AKT/GSK3β signaling in podocytes and db/db mice. Its integrated cell, transcriptomic, biochemical, and animal design provides a mechanistic framework for evaluating renal injury, although the findings remain preclinical and do not establish direct molecular binding or clinical efficacy.
FTSJ3 Loss, R-Loops, and Lung Cancer Chemosensitivity
2026-09-30
The reference study identifies FTSJ3 as a regulator of R-loop homeostasis and genome stability in lung cancer cells. Its depletion increases R-loop-associated DNA damage and enhances cisplatin sensitivity, supporting FTSJ3 as a potential biomarker and therapeutic vulnerability for further preclinical investigation.
RUNX2 Epigenetic Repression Drives OS ICB Resistance
2026-09-30
This study identifies a RUNX2–NCOR1–HDAC3 repressor complex that suppresses enhancer activity in the type I interferon pathway and limits immune checkpoint blockade efficacy in osteosarcoma. Its findings support combining selective HDAC3 inhibition with anti-PD-1 therapy to restore cGAS–STING–IFN-I signaling while managing the compensatory induction of PD-L1 and PD-L2.
LG 101506: Practical RXR Modulator Workflows
2026-09-29
Build reproducible RXR signaling assays with LG 101506, from reporter studies to pathway-focused cancer models. This workflow distinguishes direct receptor biology from hypothesis-generating applications in PD-L1 and triple-negative breast cancer research.
Human iPSC Intestinal Organoids for Pharmacokinetics
2026-09-29
The 2025 reference study establishes a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. These organoids can be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte-associated CYP and transporter activities, creating a more human-relevant platform for pharmacokinetic studies.
Kir2.1 Inhibition in Pulmonary Vascular Remodeling
2026-09-28
The reference study identifies KIR2.1 as a regulator of pulmonary artery smooth muscle cell proliferation and migration in pulmonary hypertension models. Using monocrotaline-induced pulmonary hypertension, PDGF-BB-stimulated human cells, ML133, and SB431542, the authors connect KIR2.1 activity with the TGF-β1/SMAD2/3 pathway, OPN, and PCNA expression.
H 89 2HCl in Trigeminal Pain Pathway Assays
2026-09-28
Use H 89 2HCl to test whether PKA contributes to cAMP-linked responses in trigeminal pain models—not as a stand-in for the PKC, calcium, or Piezo2 mechanisms highlighted by recent research. This workflow pairs dose-controlled inhibition with phosphorylation, calcium, and sensory readouts while flagging the concentrations and controls needed to interpret H-89’s broader kinase activity.
8700 records 6/580 page Previous Next First page 上5页 678910 下5页 Last page